Eprosartan (Eprosartanum)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Angiotensin II receptor antagonists (AT1 subtype)

Included in the formulation
  • Teveten®
    pills inwards 
    Abbott Helskea Products BV     Netherlands
    • АТХ:

    C.09.C.A   Angiotensin II antagonists

    C.09.C.A.02   Eprosartan

    Pharmacodynamics:

    It blocks angiotensin II receptors (subtype AT1) in the vessels, heart, kidney and adrenal cortex. Prevents development and weakens the action of angiotensin II, inhibits the activity of the renin-angiotensin system. Reduces arterial vasoconstriction, general peripheral resistance of blood vessels, pressure in a small circle of blood circulation, reabsorption of sodium and water in the proximal segment of the renal tubules, secretion of aldosterone, endothelin, arginine-vasopressin.

    Has hypotensive, vasodilating, nephroprotective effect, reducing the excretion of albumins, increases the rate of glomerular filtration and renal blood flow. With prolonged use suppresses the proliferation of smooth muscle vessels and myocardium caused by angiotensin II. Does not change the lipid, purine and carbon metabolism. Dose-dependent decreases blood pressure in patients with arterial hypertension I and II severity.

    The antihypertensive effect after a single dose lasts up to 24 hours,Stabilized with regular use after 2-3 weeks and is not accompanied by an increase in heart rate. Does not cause withdrawal syndrome after discontinuation.

    Pharmacokinetics:

    Not completely absorbed from the digestive tract, bioavailability is up to 13%. When taken on an empty stomach, the maximum concentration in blood plasma is achieved after 1-2 hours, eating slows down absorption and reduces by 25% her. It binds to plasma proteins by 98%. The half-life is 5-9 hours. Metabolism in the liver. It is excreted through the intestine (90%) and kidneys (10%, of which 20% in the form of acylgucuronide). With prolonged use, cumulates.

    Indications:

    Arterial hypertension (monotherapy or in combination with blockers of slow calcium channels or thiazide diuretics).

    ICD-10

    IX.I10-I15.I15   Secondary Hypertension

    IX.I10-I15.I10   Essential [primary] hypertension

    Contraindications:

    Stenosis of the artery of a single kidney, primary aldosteronism, individual intolerance, pregnancy, breast-feeding.

    Carefully:

    With stenosis of the aortic or mitral valve, hypertrophic cardiomyopathy, ischemic heart disease, severe heart failure, bilateral renal artery stenosis or renal artery stenosis of the only kidney, renal failureclearance creatinine less than 30 ml / min), hyperkalemia.

    Pregnancy and lactation:

    Recommendations for FDA - category D. Contraindicated in pregnancy and lactation.

    Dosing and Administration:

    Inside, regardless of food intake, 600-800 mg once a day (in the morning). The duration of treatment is not limited.

    The highest daily dose is 1200 mg.

    Side effects:

    Central and peripheral nervous system: headache, dizziness, asthenia.

    Respiratory system: rhinitis.

    The cardiovascular system: postural hypotension.

    Digestive system: dyspeptic disorders, vomiting, diarrhea.

    Allergic reactions.

    Overdose:

    Symptoms: arterial hypotension.

    Treatment: symptomatic.

    Interaction:

    When combined with blockers of slow calcium channels and thiazide diuretics, an increase in hypotensive action.

    When used simultaneously with non-steroidal anti-inflammatory drugs, there is a chance of developing acute renal failure.

    Special instructions:

    Monitoring of kidney function.

    Instructions
    Up